Can Glioblastoma Metastasize Outside the CNS?
Yes, glioblastoma can metastasize outside the central nervous system, but this is exceedingly rare, occurring in less than 2% of cases. 1, 2
Key Clinical Facts
While the major clinical guidelines 3, 4 do not specifically address extracranial metastasis (reflecting its rarity in routine practice), recent case series and institutional experiences confirm this phenomenon occurs and may be increasing in frequency as survival improves.
When to Suspect Extracranial Metastasis
Maintain high clinical suspicion in these specific scenarios:
- Long-term survivors (>18-24 months from diagnosis) 1, 2
- Young patients who have undergone multiple surgical resections 5
- Patients with venous sinus invasion at initial presentation 6
- Development of unexplained systemic symptoms: bone pain, lymphadenopathy, respiratory symptoms, or subcutaneous masses 1, 2, 7
Most Common Metastatic Sites
The documented pattern of spread includes:
- Cervical lymph nodes (most common) 1, 2, 8
- Bone (spine, pelvis, skull, sternum) 2, 5
- Lungs 2, 7
- Scalp/surgical site soft tissues 1, 7
- Liver, parotid gland, and rarely cardiac structures 1, 2
Mechanisms of Spread
Extracranial dissemination likely occurs through:
- Hematogenous routes following surgical manipulation and breach of CNS barriers 2, 5
- Lymphatic pathways 2
- Direct venous sinus invasion providing direct vascular access 6
High-Risk Molecular Features
Specific genomic alterations associated with extracranial metastasis include:
- TP53 mutations 1, 2
- Mesenchymal/gliosarcoma-like differentiation 1
- MET and CDK6 amplifications 7
- PD-L1 expression 1
- Tumor stemness markers (Nestin, CD44) 7
Diagnostic Approach
When extracranial metastasis is suspected, obtain:
- Whole-body 18F-FDG PET/CT for systemic staging 1
- FET PET-CT (if available) for more specific glioma detection 8
- Histopathological confirmation of suspicious lesions is essential, as imaging alone is insufficient 1
Prognosis and Management
Median survival after diagnosis of extracranial metastasis is poor (5.9-7 months) 2, 5. However:
- Multimodal treatment extends survival: combination of chemotherapy and radiotherapy to metastatic sites improves outcomes 2, 5
- Leptomeningeal disease (present in 50% of cases with extracranial spread) correlates with worse prognosis 2
- Targeted therapies based on molecular profiling should be explored, though evidence remains limited 2
Critical Pitfall
Do not dismiss systemic symptoms in glioblastoma patients as unrelated to their primary diagnosis, especially in younger patients or those surviving beyond 18 months. The rarity of this phenomenon can lead to delayed diagnosis and missed opportunities for palliative intervention.